Pfizer: Performance Is Improving, But Secular Issues Persist (Rating Upgrade) Aug. 23, 2024 4:29 AM ET Pfizer Inc. (PFE) Stock , PFE:CA Stock PFE , PFE:CA 17 Comments 3 Likes KM Capital ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

I can sum up Pfizer's (NYSE: PFE) stock performance over the last couple of years in one word (and only three letters): ugh. Shares of the big drugmaker have plunged more than 50% since the high ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See why I rate PFE stock as a Hold.

This was the stock's third consecutive day of losses.

The stock is down by 56% since 2022. Although Pfizer has made some efforts to turn things around, ... Pfizer's poor performance since 2022 is largely due to its coronavirus portfolio.

Plus, the overlapping forecast for 2024 and 2025 are, to an extent, a mirage; after removing non-recurring items from this year's forecast performance, Pfizer thinks that its revenue could grow by ...

Moderna, Pfizer and Merck stocks moved mostly sideways after RFK Jr. abruptly fired CDC's vaccine policy advisors. Investors are now waiting for news on how a reconstituted ACIP committee will ...